Search
Now showing items 1-2 of 2
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
(2015)
Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful ...